Welcome to our dedicated page for NovaBay Pharmaceuticals news (Ticker: NBY), a resource for investors and traders seeking the latest updates and insights on NovaBay Pharmaceuticals stock.
NovaBay Pharmaceuticals, Inc. (symbol: NBY) is a pioneering biopharmaceutical company dedicated to the development, commercialization, and sale of non-antibiotic anti-infective products. The company's core focus lies in addressing the unmet therapeutic needs of the global eye care market. NovaBay has successfully introduced two distinct product categories: the Neutrox™ family of products and Aganocide® compounds.
The Neutrox™ family is spearheaded by Avenova™, a prescription lid and lash hygiene product designed for managing chronic eye conditions such as blepharitis and meibomian gland dysfunction, commonly known as dry eye syndrome. Affecting an estimated 30 million Americans, these conditions represent a substantial annual market potential, which NovaBay estimates to be around $500 million. Avenova is available for order in 90% of all pharmacies across the United States and is gaining market traction through its 35 medical direct sales representatives under veteran leadership.
Additionally, the Neutrox™ family includes NeutroPhase® for wound care and CellarX™ for dermatology applications. The Aganocide® compounds are led by Auriclosene™, further showcasing NovaBay's innovative approach to non-antibiotic therapies.
NovaBay's flagship product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to possess broad antimicrobial properties. It effectively removes foreign material, including microorganisms and debris from the skin around the eye, making it a valuable tool for eyecare professionals to manage blepharitis and dry-eye disease. Avenova Spray is available to consumers both through online distribution channels and as a prescription product dispensed by eyecare professionals.
NovaBay Pharmaceuticals operates two main segments: Eyecare, and Wound Care and Skincare. This diversified approach allows the company to leverage its expertise in antimicrobial solutions across multiple therapeutic areas, thereby expanding its market reach and impact.
Financially, NovaBay continues to strengthen its market position through strategic partnerships and continuous innovation. The company's relentless pursuit of excellence in eyecare and skincare underscores its commitment to improving patient outcomes globally.
NovaBay Pharmaceuticals (NYSE American: NBY) announces a feature of its Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on QVC's "Cheers! to Shopping with Leah and Shawn" on
NovaBay Pharmaceuticals (NBY) has engaged a leading Chinese marketing firm for integrated marketing and branding services for its DERMAdoctor skincare products. This collaboration includes managing DERMAdoctor's retail store on Tmall.com, China's top B2C online retailer, starting March 1, 2022. The marketing strategy aims to enhance brand awareness by leveraging social media and influencers, targeting a burgeoning functional skincare market projected to exceed $100 billion by 2024.
NovaBay Pharmaceuticals (NBY) has appointed Dr. Audrey Kunin and Julie Garlikov to its Board of Directors, enhancing its leadership in the skincare and eyecare markets. Dr. Kunin, previously Chief Product Officer, has significant experience in product formulation from her time at DERMAdoctor. Garlikov brings over 25 years of marketing expertise in health and beauty, while Yongxiang Zheng fills the vacancy left by Paul Li. The changes are aimed at leveraging industry insights to boost growth in the OTC market. NovaBay sees a path to profitability following the DERMAdoctor acquisition.
NovaBay Pharmaceuticals has announced that its Special Meeting of Stockholders, initially held on
NovaBay Pharmaceuticals (NYSE: NBY) expands its Avenova brand with the launch of Avenova Lubricating Eye Drops, targeting the growing dry eye market projected to reach
NovaBay Pharmaceuticals (NYSE American: NBY) will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The company aims to provide insights into its expansion strategy following its acquisition of DERMAdoctor in November 2021. CEO Justin Hall projects sales to double in 2022, driven by the transition of Avenova from prescription to over-the-counter sales and plans to launch at least four new products in the first half of 2022. A webcast of the presentation will be available on the company’s website starting January 10, 2022, at 7:00 a.m. Eastern time.
NovaBay Pharmaceuticals (NBY) has adjourned its Special Meeting of Stockholders, originally held on December 17, 2021, to January 14, 2022. This extension aims to allow more time for stockholders to vote on Proposal Two, which seeks to increase the authorized common stock from 100 million to 150 million shares. Although 83.5% of shares voted supported this proposal, it fell short of the required 50% of all outstanding shares. Stakeholders are encouraged to vote before the reconvened meeting.
NovaBay Pharmaceuticals (NBY) announces that its DERMAdoctor’s Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm has received the National Eczema Association’s Seal of Acceptance. This product is designed to alleviate eczema symptoms, benefiting approximately 31 million Americans affected by the condition. The balm includes 1% colloidal oatmeal and an advanced complex of ceramides. Dr. Audrey Kunin emphasizes the product's efficacy for both adults and children, with plans for an appearance on QVC in February 2022.
NovaBay Pharmaceuticals (NBY) announces CEO Justin Hall's letter to stockholders regarding the acquisition of DERMAdoctor. This strategic move is set to double NovaBay's revenues and expedite its path to profitability with expected annual revenues of $20 million. The acquisition enhances product offerings, particularly in the skincare market, which is projected to reach $185 billion by 2027. NovaBay plans to leverage DERMAdoctor's distribution networks to expand internationally. A Special Meeting of Stockholders is scheduled for December 17, 2021, to vote on proposals related to the $15 million financing for this acquisition.
FAQ
What is the current stock price of NovaBay Pharmaceuticals (NBY)?
What is the market cap of NovaBay Pharmaceuticals (NBY)?
What does NovaBay Pharmaceuticals do?
What is Avenova?
Where can I buy Avenova?
What are the main segments in which NovaBay operates?
What is the market potential for Avenova?
What are NeutroPhase and CellarX?
What are Aganocide compounds?
How is Avenova beneficial for eye care?
Who leads the sales efforts for Avenova?
What is the main focus of NovaBay Pharmaceuticals?
